Clinical and Pathologic Characteristics of the 73 Patients
| Characteristic | Data |
| Age at PET/CT (y) | |
| Median | 66 |
| Range | 45–91 |
| PSA before surgery | |
| Median (ng/mL) | 13.9 |
| Range (ng/mL) | 0.22–909 |
| 10 ng/mL (n) | 28 (38.5%) |
| ≥10 to <20 ng/mL (n) | 18 (24.5%) |
| ≥20 ng/mL (n) | 27 (37%) |
| Gleason score (n) | |
| ≤6 | 2 (2.5%) |
| 7 | 27 (37%) |
| ≥8 | 44 (60%) |
| Initial tumor stage* (n) | |
| T1–T2a | 14 (19%) |
| T2b–T2c | 8 (11%) |
| T3a | 20 (27.5%) |
| T3b–T4 | 8 (11%) |
| N1 | 6 (8%) |
| Unknown | 17 (23%) |
| NCCN risk group (n) | |
| Intermediate | 11 (15%) |
| High | 33 (45%) |
| Very high | 22 (30%) |
| N1 | 7 (9.5%) |
| Prior ADT (n) | 7 (9.5%) |
↵* Clinical examination and CT/MRI.
NCCN (National Comprehensive Cancer Network) risk groups: intermediate (T2b–T2c, or Gleason score 3 + 4 = 7 [grade group 2], or Gleason score 4 + 3 = 7 [grade group 3], or PSA = 10–20 ng/mL); high (T3a, or Gleason score 8 [grade group 4], or Gleason score 9–10 [grade group 5], or PSA > 20 ng/mL); very high (T3b–T4, or primary Gleason pattern 5 [grade group 5], or >4 cores with Gleason score 8–10 [grade group 4 or 5]).